TricDB

gilteritinib

Drug Code : 22020124112
Drug Brand : Xospata
Company : Astellas Pharma Inc
Approved by : NCCN
Approval Time :
Direct Target : FLT3
Drug Type : Single-target inhibitor
Gene : FLT3
Alteration : Codon 835 Missense
Indications :
Mechanism Of Action :
Gilteritinib is a small molecule that inhibits multiple receptor tyrosine kinases, including FMS-like tyrosine kinase 3 (FLT3). Gilteritinib demonstrated the ability to inhibit FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3-ITD, tyrosine kinase domain mutations (TKD) FLT3-D835Y and FLT3-ITD-D835Y, and it induced apoptosis in leukemic cells expressing FLT3-ITD.
Clinical Trial :
Efficacy & Safety :
Structure :
 Related Targets and Diseases
Drug Name Gene Disease Negative Genotypes Drug Brand Drug Type
Reference List :


Approval Notifications
Hot words
Terms of Use
Privacy Policy
biomeddb.org © 2025 Hubei University
Email: argyjbao@hotmail.com & skysky@hubu.edu.cn